I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Teresa Mccarthy Biography and Net Worth

Insider of Avidity Biosciences

Teresa McCarthy, Chief Human Resources Officer, joined Avidity Biosciences in August 2020. Ms. McCarthy is responsible for developing and executing human resource strategies in support of Avidity’s overall business plan and strategic direction. She brings to Avidity decades of experience as an organizational development and human resources consultant in the life science industry. Ms. McCarthy has worked with biotech and healthcare companies at all stages of development via her consulting firm, McCarthy Consultants Inc., and her long-term partnership with The Leadership Edge, Inc. Prior to consulting, Ms. McCarthy held leadership positions at Edwards Lifesciences, Baxter Cardiovascular Group, and IVAC Corporation and received an M.A. degree in Organizational Communication with an emphasis in International Business from San Diego State University.

What is Teresa Mccarthy's net worth?: The estimated net worth of Teresa Mccarthy is at least $2.68 million as of December 16th, 2024. Ms. Mccarthy owns 94,018 shares of Avidity Biosciences stock worth more than $2,684,214 as of December 30th. This net worth approximation does not reflect any other assets that Ms. Mccarthy may own. Learn More about Teresa Mccarthy's net worth.
How do I contact Teresa Mccarthy?: The corporate mailing address for Ms. Mccarthy and other Avidity Biosciences executives is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. Avidity Biosciences can also be reached via phone at 858-401-7900 and via email at [email protected]. Learn More on Teresa Mccarthy's contact information.
Has Teresa Mccarthy been buying or selling shares of Avidity Biosciences?: In the last ninety days, Teresa Mccarthy has sold $3,073,000.00 of Avidity Biosciences stock. Most recently, Teresa Mccarthy sold 25,000 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $33.26, for a transaction totalling $831,500.00. Following the completion of the sale, the insider now directly owns 94,018 shares of the company's stock, valued at $3,127,038.68. Learn More on Teresa Mccarthy's trading history.
Who are Avidity Biosciences' active insiders?: Avidity Biosciences' insider roster includes Sarah Boyce (President & CEO), W. Flanagan (Insider), Arthur Levin (Insider), Michael MacLean (Chief Financial and Chief Business Officer), Teresa Mccarthy (Insider), and Tamar Thompson (Director). Learn More on Avidity Biosciences' active insiders.
Are insiders buying or selling shares of Avidity Biosciences?: During the last year, insiders at the biotechnology company sold shares 36 times. They sold a total of 988,429 shares worth more than $33,473,368.19. The most recent insider tranaction occured on December, 18th when insider W. Michael Flanagan sold 12,742 shares worth more than $416,153.72. Insiders at Avidity Biosciences own 3.7% of the company. Learn More about insider trades at Avidity Biosciences.
Information on this page was last updated on 12/18/2024.

Teresa Mccarthy Insider Trading History at Avidity Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/16/2024	Sell	25,000	$33.26	$831,500.00	94,018
11/18/2024	Sell	25,000	$41.14	$1,028,500.00	94,018
10/16/2024	Sell	25,000	$48.52	$1,213,000.00	94,018
9/23/2024	Sell	13,153	$44.00	$578,732.00	69,018

Teresa Mccarthy Buying and Selling Activity at Avidity Biosciences

Avidity Biosciences Company Overview

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $28.55

$28.36

$29.99

50 Day Range

MA: $40.66

$30.11

$52.50

2 Week Range

Now: $28.55

$8.86

$56.00

Volume

466,789 shs

Average Volume

1,305,174 shs

Market Capitalization

$3.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

First JFK… next Elon?

From Porter & Company | Ad

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.